THE BABRAHAM RESEARCH CAMPUS REMAINS OPEN FOR TENANT COMPANIES AND THEIR KEY WORKERS. Visitors and deliveries are to be kept to a minimum and social distancing advice adhered too. Updates on the Babraham Institute can be found here.
The Babraham Research Campus is considered to be one of the UK’s leading campus' to support early-stage bioscience enterprise and is distinct in its co-location of bioscience companies with the Babraham Institute. World class research and business come together to promote innovation and strengthen links between academia and the commercial world. The Babraham Research Campus is managed and developed by Babraham Bioscience Technologies Ltd (BBT).
Working in close collaboration, scientists from the Tate Group, Imperial College London, and drug discovery and development company, Mission Therapeutics, have discovered the first exquisitely selective probe for a deubiquitylating enzyme (DUB).
BenevolentAI today announced the publication of further experimental data in support of its AI-derived hypothesis for baricitinib as a potential treatment for COVID-19 in the Journal: EMBO Molecular Medicine.
(+44) 1223 496 000
Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom
01223 813 557